{"id":"panzyga-10-intravenous-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion site reactions"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Aseptic meningitis"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a 10% liquid IVIG preparation, Panzyga contains polyvalent immunoglobulins derived from pooled human plasma that can neutralize pathogens, block pathogenic antibodies, and modulate complement activation and inflammatory cytokine production. It is used in primary and secondary immunodeficiency states as well as autoimmune and inflammatory conditions where immune dysregulation is pathogenic. The mechanism involves both replacement of deficient antibodies and immunomodulatory effects on B cells, T cells, and innate immune pathways.","oneSentence":"Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:29.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency disorders"},{"name":"Secondary immunodeficiency"},{"name":"Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"}]},"trialDetails":[{"nctId":"NCT07220915","phase":"PHASE3","title":"Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections","status":"NOT_YET_RECRUITING","sponsor":"Octapharma","startDate":"2025-12","conditions":"Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions","enrollment":360},{"nctId":"NCT04929236","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2023-10-01","conditions":"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":30},{"nctId":"NCT03166527","phase":"PHASE3","title":"Panzyga in CIDP Administered at Different Infusion Rates","status":"UNKNOWN","sponsor":"Vera Bril","startDate":"2017-06-01","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Panzyga, 10% Intravenous Solution","genericName":"Panzyga, 10% Intravenous Solution","companyName":"Octapharma","companyId":"octapharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Panzyga is an intravenous immunoglobulin (IVIG) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and reduce inflammation. Used for Primary immunodeficiency disorders, Secondary immunodeficiency, Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}